Chris Ryan
A federal jury in Delaware has reportedly found that Japan’s Nippon Shinyaku infringed upon Sarepta’s (NASDAQ:SRPT) patent for its Duchenne muscular dystrophy, or DMD, drug Vyondys 53 and awarded Sarepta $115.2M in damages.
The jury also rejected Shinyaku’s claim that